Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/341575
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampSouza, Carmino Antonio de-
dc.typeArtigopt_BR
dc.titleA subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohortpt_BR
dc.contributor.authorTavares, R.-
dc.contributor.authorDe Souza, C.A.-
dc.contributor.authorPaley, C.-
dc.contributor.authorBouard, C.-
dc.contributor.authorTiwari, R.-
dc.contributor.authorPasquini, R.-
dc.subjectMielofibrose primáriapt_BR
dc.subject.otherlanguagePrimary myelofibrosispt_BR
dc.description.abstractIntroduction: Ruxolitinib has been approved for the treatment of myelofibrosis (MF). In this study, we present safety and efficacy findings from an analysis of 104 patients with intermediate- and high-risk MF in a Brazilian cohort of the JUMP study who received treatment with ruxolitinib. Methods: JUMP is a single-arm, open-label, phase IIIb, expanded-access study. The primary endpoint was to evaluate the safety and tolerability (frequency, duration, and severity of adverse events [AEs]) of ruxolitinib. Results: All of the 104 patients received the treatment. Median duration of exposure was 35.8 months. The most common hematologic AEs were anemia (57.7), thrombocytopenia (38.5%), neutropenia (11.5%), and leukopenia (9.6%). Second malignancies (all grades) occurred in 19.2% of patients (n = 20). Serious AEs were reported in 62.5% of patients (n = 65). The proportions of patients with ≥50% reduction from baseline in palpable spleen length at weeks 24 and 48 were 62.7% and 69.2%, respectively. The mean change from the baseline in the Functional Assessment of Cancer Therapy (FACT)-Lymphoma total score was 10.8 [15.6%] at week 4, 12.6 [14.1%] at week 24, and 12.2 [14.3%] at week 48. The mean change from the baseline for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale was 3.9 [42.8%] at week 4, 4.9 [29.9%] at week 24, and 4.7 [28%] at week 48. At week 48, the estimated progression-free survival, leukemia-free survival, and overall survival probabilities were 91%, 91% and 93%, respectively Overall, 21 deaths were observed in the present study. Conclusion: Findings from this study suggest that ruxolitinib could be evaluated as a standard-of-care treatment for the MF population in need of a viable treatment optionpt_BR
dc.relation.ispartofHematology, transfusion and cell therapypt_BR
dc.publisher.citySão Paulo, SPpt_BR
dc.publisher.countryBrasilpt_BR
dc.publisherElsevierpt_BR
dc.date.issued2020-
dc.date.monthofcirculationJan./Mar.pt_BR
dc.language.isoengpt_BR
dc.description.volume42pt_BR
dc.description.issuenumber1pt_BR
dc.description.firstpage46pt_BR
dc.description.lastpage53pt_BR
dc.rightsFechadopt_BR
dc.sourceSCOPUSpt_BR
dc.identifier.issn2531-1379pt_BR
dc.identifier.eissn2531-1387pt_BR
dc.identifier.doi10.1016/j.htct.2019.01.009pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S2531137919300549pt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2020-05-16T12:43:40Z-
dc.date.accessioned2020-05-16T12:43:40Z-
dc.description.provenanceSubmitted by Sanches Olivia (olivias@unicamp.br) on 2020-05-16T12:43:40Z No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2020-05-16T12:43:40Z (GMT). No. of bitstreams: 0 Previous issue date: 2020en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/341575-
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordRuxolitinibpt_BR
dc.subject.keywordJUMPpt_BR
dc.subject.keywordBrazilpt_BR
dc.identifier.source2-s2.0-85067501709pt_BR
dc.creator.orcid0000-0001-8656-8374pt_BR
dc.type.formArtigo originalpt_BR
dc.description.otherSponsorshipsem informaçãopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.